RecruitingAccepts healthy volunteers

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

Mayo Clinic · NCT06557057

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Status re-checked against ClinicalTrials.gov within the last 12 hours.

This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.

Being studied: Non-Interventional Study

Conditions: HER2-Positive Breast Carcinoma

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

Post-menopausal women with hormone receptor positive breast cancer, ductal carcinoma in situ (DCIS), or with other high risk breast conditions. Post-menopause will be defined as women who experience 12 months of amenorrhea or have undergone bilateral salpingo-oophorectomy.

25 women who are planning to start or are within 6 months of starting treatment with aromatase inhibitors, after consultation in breast clinic and cancer center.
25 women who will be starting Tamoxifen (comparative group)
25 healthy post menopausal women will also be recruited.

Exclusion Criteria

Established diagnosis of diabetes
Therapy with medications that could affect glucose metabolism
Screening fasting glucose ≥ 126 mg/dl, and/or HbA1c ≥ 6.5%
History of upper GI surgery that alters gastric emptying or causing malabsorption e.g., bariatric surgery, fundoplication

Mayo Clinic in Rochester
Rochester, MN 55905
Site contact: Clinical Trials Referral Office · 855-776-0015 · mayocliniccancerstudies@mayo.edu

Clinical Trials Referral Office · 855-776-0015 · mayocliniccancerstudies@mayo.edu